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Abstract 
Rationale: Ultrasound-mediated opening of the Blood-Brain Barrier(BBB) has shown exciting 
potential for the treatment of Alzheimer’s disease(AD). Studies in transgenic mouse models have 
shown that this approach can reduce plaque pathology and improve spatial memory. Before clinical 
translation can occur the safety of the method needs to be tested in a larger brain that allows 
lower frequencies be used to treat larger tissue volumes, simulating clinical situations. Here we 
investigate the safety of opening the BBB in half of the brain in a large aged animal model with 
naturally occurring amyloid deposits.  
Methods: Aged dogs naturally accumulate plaques and show associated cognitive declines. 
Low-frequency ultrasound was used to open the BBB unilaterally in aged beagles (9-11yrs, n=10) in 
accordance with institutionally approved protocols. Animals received either a single treatment or 
four weekly treatments. Magnetic resonance imaging(MRI) was used to guide the treatments and 
assess the tissue effects. The animals underwent neurological testing during treatment follow-up, 
and a follow-up MRI exam 1 week following the final treatment.  
Results: The permeability of the BBB was successfully increased in all animals (mean 
enhancement: 19±11% relative to untreated hemisphere). There was a single adverse event in the 
chronic treatment group that resolved within 24 hrs. Follow-up MRI showed the BBB to be intact 
with no evidence of tissue damage in all animals. Histological analysis showed comparable levels of 
microhemorrhage between the treated and control hemispheres in the prefrontal cortex 
(single/repeat treatment: 1.0±1.4 vs 0.4±0.5/5.2±1.8 vs. 4.0±2.0). No significant differences were 
observed in beta-amyloid load (single/repeat: p=0.31/p=0.98) although 3/5 animals in each group 
showed lower Aβ loads in the treated hemisphere.  
Conclusion: Whole-hemisphere opening of the BBB was well tolerated in the aged large animal 
brain. The treatment volumes and frequencies used are clinically relevant and indicate safety for 
clinical translation. Further study is warranted to determine if FUS has positive effects on naturally 
occurring amyloid pathology. 
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Introduction 
Ultrasound-mediated opening of the 
Blood-Brain Barrier (BBB) is an area of increasing 
research due to its potential to significantly impact the 
treatment of brain disorders. The BBB regulates the 
passage of molecules from the vasculature to the brain 
parenchyma to maintain the brain environment, and 
in doing so prevents most intravenously- 
administered therapeutic agents from reaching the 
brain tissue in therapeutically relevant quantities [1]. 
One method to circumvent the BBB is to transiently 
open it using ultrasound [2]. When ultrasound 
interacts with intravenous diagnostic ultrasound 
contrast agents, micron-sized gas spheres known as 
‘microbubbles’, it causes them to oscillate in the 
vasculature. The microbubbles stimulate the blood 
vessels in the brain and cause a transient opening 
lasting a few hours in length where therapeutics 
ranging in size from small molecule 
chemotherapeutics [3, 4, 5], to antibodies [6, 7], 
gene-delivery vectors [8, 9, 10] and stem cells [11] can 
be delivered. Investigations in non-human primates 
have demonstrated a good safety profile for this 
technique [12, 13, 14], and initial clinical 
investigations in brain tumor patients are underway 
in France [15] and Canada [16]. 
These methods also show promise in the 
treatment of Alzheimer’s disease (AD). The first 
studies in mouse models of AD found that using 
ultrasound to deliver an anti-Amyloid β antibody 
resulted in a reduction of beta-amyloid (Aβ) plaque 
pathology 4 days post-treatment [6]. Interestingly, a 
later study showed that ultrasound opening of the 
BBB, in the absence of an externally administered 
therapeutic, also produced a positive effect on plaque 
load, presumably due to the treatment facilitating 
endogenous antibodies to reach the brain and/or 
activation of microglial cells [17]. Further, repeated 
opening of the BBB with ultrasound alone improves 
memory in two different transgenic mouse models of 
AD [18, 19].  
Unlike mouse models of AD, which rely on 
genetic modification and overexpression [20], aged 
dogs naturally develop pathology and cognitive 
deficits [21]. Although the safety of this approach has 
been tested in large animals in the healthy brain [12, 
13] safety in the aged, pathologic brain remains to be 
confirmed. It is unclear from the current literature if 
the aged brain will be as robust against the 
mechanical insult from the ultrasound and 
microbubbles. In addition, the larger brain of beagles 
allows clinically relevant low frequencies that 
penetrate the skull to be used in a larger skull cavity 
without significant impact from standing waves, as is 
case in the small skull of rodents [22]. Similarly, the 
tissue volume exposed in the dog brain can simulate 
the volumes needed to be exposed in clinical 
treatments. Therefore, this natural model allows 
investigations of BBB opening for the treatment of AD 
as a precursor to clinical investigations. In this study 
we investigate the safety of single and repeated BBB 
opening treatments in aged beagles (9-11yrs), which is 
an age at which most animals will have Aβ 
deposition. The results of these treatments and a two 
week follow-up period are reported. 
Materials and Methods 
Study Design 
The objective of this study was to test the safety 
of ultrasound-mediated BBB opening in the aged 
brain with clinically relevant exposure conditions and 
treatment volumes. Aged beagle dogs (n=10, 9-11yrs, 
10.1-13.8kg) with naturally occurring amyloid 
pathology were used, in accordance with 
institutionally approved protocols (Sunnybrook 
Research Institute animal care committee) and in 
keeping with the Canadian Council on Animal Care 
guidelines on the care and use of laboratory animals. 
The animals were divided into two groups (each n=5), 
the first receiving a single treatment, and the second 
group receiving weekly treatments for four weeks. 
The effects were monitored using MRI, neurological 
testing and histological analysis. 
Animal Preparation 
The animals had a range of underlying medical 
conditions, including cancer, and this was an 
end-of-life study prior to euthanasia. Anesthesia was 
induced with acepromazine (0.2mg/kg, 
intramuscular). The animals were intubated and 
anesthesia was maintained using oxygen and 2% 
isofluorane. The carrier gas was changed to medical 
air 10 mins prior to the first treatment sonication. The 
cephalic or saphenous vein was catheterized using a 
22-20G angiocatheter. The hair on the head was 
removed using an electric razor and depilatory cream.  
The animals were mechanically ventilated 
during the treatment and imaging procedures, and 
the heart rate was monitored using a pulse oximeter. 
While anesthetized, the body temperature was 
maintained using a circulating water blanket and was 
regularly checked using a rectal thermometer. 
The animals were assigned to one of two groups. 
In the first group the animals received a single 
ultrasound treatment and then were followed for two 
weeks. After no significant adverse effects were 
observed following the single treatment, a second 
group of animals received treatments weekly for 4 
weeks, followed by a 2 week follow-up period. 
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Ultrasound Exposures 
For the treatments, the animals were positioned 
supine above an MRI-compatible three-axis 
positioning system, operationally similar to that 
described by Ellens et al [23], that would mechanically 
position the ultrasound focus by moving a 
single-element, fixed focus transducer. The 
experimental setup is illustrated in Fig.1. The 
ultrasound was generated by an in-house assembled, 
spherically curved, lead zirconate titanate (PZT) 
transducer (PZT from DeL Piezo Specialties, LLC, 
West Palm Beach, Florida), with a 75 mm diameter, 
focal-number 0.8 and fundamental frequency, f0 = 0.28 
MHz. The transducer was matched to 50 Ω, 0° at its 
fundamental frequency using an external matching 
circuit, and driven using a function generator 
(33220A; Agilent, Santa Clara, California) and an RF 
amplifier (NP2519; NP Technology, Newbury Park, 
California). Sonications were applied transcranially. 
All pressure estimates reported in this paper are 
based on the calibration of the transducer in water 
using a fiber-optic hydrophone (Precision Acoustics, 
Ltd, UK) and are not de-rated for transmission 
through the skull-bone due to the wide variation in 
cranial geometry, and hence insertion loss, between 
animals (Fig.2). The measured dimensions of the 
transducer focal spot (full-width-at-half-maximum 
pressure) were 6.5 mm in the transverse direction, and 
40 mm axially. The insertion loss at 280 kHz was 
measured in 4 of the skull caps following tissue 
harvest using the fiber-optic hydrophone system. 
Measurements of the focal pressure amplitude were 
made at a total of 20 locations across the 4 skulls and a 
mean (± S.D.) transmission of 53 ± 15% was measured.
 
 
 
Fig.1. A) Experimental setup. A coronal T2-weighted MR image shows the orientation of the transducer with respect to the subject. B) Example sonication grids 
overlaid on an axial T2-weighted MR image. Solid white circles: 2x2 grid with 4.5 mm spacing, Dashed white circles: 1x4 line with 4.5 mm spacing, Solid black circles: 
reduced, 3 point grid with 4.5 mm spacing to fit the brain geometry at the edges of the brain cavity. The dashed black line indicates the brain midline. The diameter 
of the circles is the approximate FWHM of the focal spot. C) Example pressure vs. time curve for one sonication focus, showing the peak negative pressure (free-field) 
for each burst of ultrasound. The black and red circles correspond to timepoints below (black) and at (red) the threshold for detecting ultraharmonic microbubble 
behavior. The spectra corresponding to these two bursts are overlaid in (D), where signals at 0.42 and 0.7 MHz (1.5f0 and 2.5f0) are seen in the red trace. 
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Fig.2. CT skull cross-sections (coronal) from (top) the 5 subjects in the acute treatment group, and (bottom) the 5 subjects in the repeat treatment group. The sex, 
age and weight of the subjects at the time of treatment are shown. The scale bar is 2 cm. 
 
Definity microbubbles (Lantheus Medical 
Imaging, N. Billerica, MA, USA) were used to 
potentiate the BBB opening effect and were injected 
simultaneously with the start of the ultrasound 
exposure at a dose of 0.02 ml/kg per injection. The 
mechanical positioning system used is limited in the 
speed of travel between treatment points. For the 10 
ms ultrasound bursts used in this study, the 
positioner could rapidly move to and treat up to 4 
points at 4.5 mm spacing within 1 second, allowing 
for a 1 Hz pulse repetition frequency (PRF) per point. 
A larger number of focal points could be treated in 
one sonication (one bubble injection) by reducing the 
PRF to allow more time to cycle through the targets. 
In the first animal the sonications were 3 minutes in 
length, and consisted of 10 ms bursts at a 0.33 Hz, per 
point PRF, for a total of 60 bursts per target. The 0.33 
Hz PRF allowed 3 seconds for the positioning system 
to cycle through 9 targets in a 3x3 grid with 4 mm 
spacing. The sonication pressure was fixed for the 
sonication and ranged from 0.8-1 MPa (free-field 
estimate). In the remaining 9 animals the treatment 
pressures were modulated during the sonications, 
using the control scheme reported in [24], which is 
also briefly described in the following: Microbubble 
emissions during the sonications were captured to PC 
with a sampling rate of 20 MHz and an 11 ms capture 
length using a wideband, PVDF receiver [25] 
connected to a 14 Bit PCI digitizer (ATS460, Alazar 
Tech, Pointe Claire, Quebec). After each burst the 
frequency content of the data was analyzed. Starting 
at a value of 0.6-1 MPa, the pressure was increased by 
0.016 MPa for each subsequent burst until 
ultraharmonic microbubble emissions (1.5f0 or 2.5f0) 
were detected. Prior work in rats has shown that these 
emissions precede the appearance of wideband 
emissions indicating inertial cavitation, and can thus 
be used as an internal calibration point to stay below 
the threshold for tissue damage [24]. This means that 
each sonication point received an acoustic exposure 
based on the acoustic emissions detected, thus 
minimizing the variations caused by skull thickness 
and angle of incidence [26, 27, 28]. The peak pressure 
(mean ± S.D.) reached in these sonications was 1.2 ± 
0.3 MPa. Following detection of the ultraharmonic 
signals the pressure was decreased by 50 % and 
maintained for the remainder of the sonication 
(Fig.1C, D). The actively controlled sonications were 
performed at a 1Hz PRF for a total of 2 minutes (120 
bursts per target) using 2 x 2 or 1 x 4 interleaved target 
grids with 4.5 mm spacing (Fig.1B). At the edges of 
the brain, some sonications were reduced to 3 or 2 
points to fill the remaining space without overlapping 
previous sonications. For both sonication schemes the 
sonications were repeated with new targets until the 
entire hemisphere had been treated. A minimum of 5 
minutes was allowed between sonications for the 
microbubbles from the previous injection to clear. The 
total number of sonications with separate 
microbubble injections varied between 7 and 13 per 
treatment with a mean value of 9 ± 2. The total 
number of foci sonicated in this study was 920. This 
value is the total number of focal spots required to 
cover the treated hemisphere, summed over all 
animals and all treatments. 
CT and MRI Imaging 
All animals were imaged in an x-ray computed 
tomography (CT) scanner (Aquilon ONE, Toshiba 
America Medical Systems, Inc., Tustin, California). 
The field of view was adjusted slightly based on the 
animal size and was reconstructed using a 512x 512 
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image matrix, resulting in voxel dimensions that 
varied slightly between animals but were at most 0.35 
x 0.35 x 1 mm3. The CT images were captured to allow 
better visualization of the skull geometry and porosity 
to anticipate potential issues with sound transmission 
during the treatments.  
The MRI parameters used are summarized in 
Table 1. All treatments were performed under 
MRI-guidance at 3T (Signa MR750, GE Healthcare, 
Milwaukee, Wisconsin). Baseline T1 and T2 weighted 
images were obtained and are shown for group 1 in 
Fig.3. Contrast-enhanced (CE) T1 weighted imaging 
(0.1 ml/kg Gadovist) was used to assess the integrity 
of the BBB post-treatment, and post-treatment T2 and 
T2* images were used to identify edema or 
hemorrhage. Follow-up MR imaging was performed 
one week following the final treatment, using CE-T1, 
T2 and T2* weighted imaging. The follow-up imaging 
was performed on the same MRI scanner used during 
the treatments, except in one case where the system 
was unavailable and an alternate 3T platform was 
used (MAGNETOM Prisma, Siemens Healthcare, 
Erlangen, Germany).  
 
Table 1. MRI parameters 
 GE Siemens 
Parameter T1 T2 T2* T1 T2 T2* 
Sequence type Fast spin 
echo 
Fast 
spin 
echo 
3D 
gradient 
echo 
Turbo 
spin 
echo 
Turbo 
spin 
echo 
3D 
gradient 
echo 
Echo time (ms) 14.52 58.08 3.3348 16 79 15 
Repetition time (ms) 500 3000 8.108 500 3000 27 
Echo train length 4 4 1 4 8 1 
Averages 3 1 1 2 2 2 
Field of view (cm) 14x14 14x14 14x14 14x14 14x14 14x14 
Matrix 256x256 256x256 256x256 128x128 128x128 128x128 
Slice thickness (mm) 1.5 1.5 1 1.5 1.5 1 
 
Neurological Testing 
The animals were subjected to a neurological 
exam 24 hrs after the ultrasound treatment (Group 1) 
or daily beginning 72 hrs before the first treatment 
and continuing until the study end (Group 2). The 
exam included observations of general mental status, 
posture and movement, as well as cranial nerve 
function and postural reactions. The complete 
neurological exam criteria are included in Table 2. The 
testing did not assign a numeric score as the criteria 
were assessed as pass/fail, with animals either having 
a consistent response with their prior health history or 
baseline data, or an abnormal response.  
Histological Processing and Analysis 
Two weeks following the final treatment in each 
group, the animals were deeply anesthetized and 
sacrificed using approved animal protocols. Brains 
were fixed in 4% paraformaldehyde for 48-72 hrs 
prior to transfer to phosphate buffered saline (pH 7.4) 
and storage at 4⁰C. The prefrontal cortex was 
dissected from both the left and right side for all 
animals and sectioned at 50µm using a vibratome. 
This is typically the brain region affected earliest by 
Aβ deposition in beagles [29]. Tissue was stained for 
Aβ plaques using previously published 
immunohistochemical methods [30] with 6E10 
antibody (Aβ1-16, Covance, Dedham, MA; 1:3000, 
mouse monoclonal) after the tissue was pre-treated in 
90% formic acid for 4 min [31]. Adjacent sections were 
used for microglial immunostaining with the IBA-1 
antibody (for possible inflammation, Wako Chemicals 
USA, Richmond, VA, 1:800, rabbit polyclonal) and 
Prussian blue staining to identify microhemorrhages 
using previously published protocols [32].  
Aβ and IBA-1 immunostained slides were 
imaged using an Aperio ScanScope XT digital 
slidescanner at 40x magnification to create a high 
resolution digital image. The Aperio positive pixel 
count algorithm (version 9) was used to quantify 
specific staining in 10-600x600µm2 fields. 
Quantification of Prussian blue staining was by 
counting microhemorrhages in each tissue section 
using a 20X objective and counting within 10 
fields/section. Prussian blue labeling within 2 cell 
diameters of a blood vessel was considered a 
microhemorrhage. 
Statistical Analysis 
Although the sample size was small, a repeated 
t-test was used to compare the left and right 
hemisphere Aβ loads in the two treatment groups and 
in all 10 animals. 
Results  
The treatment parameters, including the number 
of microbubble doses and sonication foci targeted, as 
well as a summary of adverse events, are summarized 
on a per-animal basis in Table 3. 
CT and MRI findings 
CT images from the 10 animals showing coronal 
cross-sections of the skull bone are shown in Fig.2. It 
can be seen that the bone thickness and geometry 
varied substantially between animals. The dog skulls 
had a mean thickness (± S.D.) of 3.2 ± 1.1 mm 
(maximum 9.2 mm), estimated over 25 
locations/skull, and a mean density (± S.D.) of 2172 ± 
509 kg/m3 (maximum 3691 kg/m3). The brain cavities 
of the 10 dog skulls were measured to be 42.5 ± 1.6 
mm deep, 52.4 ± 1.5 mm wide and 71.2 ± 3.6 mm long. 
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Table 2. Neurological testing template 
Mental Status:  Categorize overall mental status: 
BAR (bright, alert, responsive) / QAR (quiet, alert responsive) / Stuporous (only responsive to painful stimuli) / Comatose (non-responsive) 
Body Posture:  Describe any abnormal body posture: 
Head Tilt (L/R) / Head Turn (L/R) / Circling (L/R) 
Gait: Describe any abnormalities in gait, specifying involved limb(s): 
Paresis (weakness of voluntary movement) / Paralysis (absence of voluntary movement) / Lameness (uneven gait caused by pain or stiffness) 
Ataxia:  Describe any irregular or inconsistent movements: 
Proprioceptive (scuffing or dragging the paws on the ground, knuckling over, crossing over, or interference) / Vestibular (unable to walk in a 
straight line) / Cerebellar (undershooting or overshooting of intended position with paw) 
CRANIAL NERVES   
Pupil (CN III): Record size, symmetry and shape of pupils 
Menace (CN II/VII): Make a threatening gesture at the eye to induce a blink 
PLR (CN II/III): Shine a light into one eye and look for pupil constriction in both eyes 
Strabismus (CN III/IV/VI): Eyes are not aligned due to lack of coordination between the extraocular muscles 
Corneal Reflex (CN V/VI): Gently touch the cornea with a moist soft cotton swab to induce global retraction 
Jaw Tone (CN V): Observe and palpate muscles of mastication for any swelling, atrophy, or asymmetry. Animal many not be able to close mouth if there is bilateral 
weakness 
Maxillary & Mandibular 
(CN V): 
Gently pinch the lips and look for retraction of the lips. Also, touch the medial nasal mucosa with a hemostat and look for retraction of the head 
Palpebral (CN V/VII) Gently touch the medial & lateral canthus of the eye to induce a blink response 
Nystagmus (CN VIII): Observe the eyes for nystagmus while moving the head slowly laterally in both directions, and up and down. 
POSTURAL REACTIONS   
Proprioceptive positioning: With the animal standing, turn over one paw and place the back of the paw on the floor. The animal should quickly correct the position of the paw. 
Hopping: Hold the animal so that all of its weight is supported by one limb and move the animal forward or laterally. The animal should make a quick, 
smooth step in response 
Wheelbarrow: Lift the hind limbs off the ground and gently push the animal forward. The animal should make alternating steps with its forelimbs. 
Extensor Postural Thrust: Hold the animal leaving just the hind limbs on the ground and gently push the animal backward. The animals should make coordinated steps 
backwards. 
Placing Reactions: Cover the animal's eyes and move the animal towards the edge of a table. The animal should place their paws on the table as soon as there is 
contact 
 
 
 
Fig.3. Baseline T1-weighted and T2-weighted axial MR images for the 5 subjects in the acute treatment group. The images for subjects 1, 2 and 3 have been resliced 
from oblique image stacks. The scale bar is 2 cm. 
 
To compare, the average thickness and density 
of the supraorbital region of 8 ex vivo human skulls (4 
skull caps and 4 full skulls) in our laboratory was 
extracted from existing CT data. The human skulls 
were found to be approximately twice as thick (6.4 ± 
1.8 mm, maximum 20.3 mm) and were similar but not 
quite as dense (1900 ± 373 kg/m3, maximum 2975 
kg/m3) as the dog skulls. The brain cavities of the 4 
full human skulls were 108.4 ± 4.2 mm deep, 137.2 ± 
9.9 mm wide and 162.3 ± 5.2 mm long. Despite the 
bone morphology, the permeability of the BBB was 
successfully increased unilaterally using transcranial 
ultrasound (Fig.4). A mean enhancement of 19 ± 11% 
was observed across all treatments relative to the 
untreated hemisphere. Heterogeneous patterns of 
enhancement were observed in all animals. 
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Enhancement was not seen in the white matter tracts, 
which is consistent with investigations of BBB 
opening in primates [12] and can be attributed to the 
fact that white matter is poorly vascularized resulting 
in limited signal from the extravasated contrast agent. 
The post-treatment images for animal #4 are missing 
due to a data loss, but the degree of enhancement and 
the heterogeneity of the enhancement were in keeping 
with the other four animals in the single treatment 
group. The mean intensity across the entire 
hemisphere relative to the control hemisphere is 
shown for each treatment and follow-up in Fig.5. 
These are expressed as (1-mean_intensitytreated/ 
mean_intensityuntreated)*100%, and thus negative 
values can occur when the mean intensity of the 
treated side is lower than the control side. Also shown 
are the mean intensity in an unsonicated region 
(usually in the olfactory bulb or cerebellum) of the 
treated hemisphere relative to the same region on the 
treated side. This control region is included because in 
some cases there were substantial differences in the 
intensity of the MR images resulting from the 
positioning of the surface coil. For example, the coil 
placement during the follow-up imaging of animal #6 
resulted in an intensity gradient left to right across the 
brain. Examining only the treated vs. untreated 
intensities makes it appear that there is enhancement 
in the treated region. Examining the unsonicated 
control region, it can be seen that the higher intensity 
in the left hemisphere is unrelated to the treatment 
region. The heterogeneity of the BBB opening is 
reflected by the large standard deviations in the 
treated hemispheres. 
At one week post treatment, the BBB was fully 
intact in all animals and there were no indications of 
damage to the brain tissue on the T2 and T2* weighted 
images. In the first animal, thermal damage was seen 
in the overlying muscle at follow-up and was 
confirmed at necropsy. This was attributed to a 
technical error that saw higher pressure exposures (>2 
MPa), interleaved at several locations, applied in the 
absence of injected microbubbles. Because there were 
no bubbles in circulation, there was no associated 
damage to the brain tissue observable by MRI or in 
histology. Thermal damage was not seen in any of the 
remaining animals, where the sonications were 
correctly performed. 
 
 
Fig.4. MR (axial) images from the 5 subjects in the acute treatment group acquired immediately post-treatment and at 7 days post-treatment. Contrast-enhanced 
(CE) T1w images are shown on Day 0, and CE-T1w, T2w and T2* weighted images are shown for Day 7. The Day 0 image for subject #1 has been resliced from an 
oblique plane. The Day 7 images for subject #3 were acquired using a different MRI scanner (Siemens Prisma). The scale bar is 2 cm. 
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Neurological testing and adverse events 
All animals were alert and responsive following 
the treatments. Gait and postural reactions were 
consistent with baseline testing or the animals’ prior 
health histories, and cranial nerve testing was normal 
in all animals.  
One minor adverse event was observed. 24 hr 
following the second treatment, the first animal in the 
chronic treatment group had bloody urine and was 
vomiting. In consultation with the institutional 
veterinarian this animal was given IV fluids and 
started on oral antibiotics as a precaution. The 
symptoms were resolved 24 hours following. As the 
first animal in the repeat treatment group, the 
treatment times for this animal were longer as the 
treatment process had not been optimized. The 
prolonged anesthesia time and the number of MRI 
contrast agent injections were thought to have 
contributed to the adverse reaction. For the remaining 
treatments the MR imaging protocols on treatment 
days were optimized to reduce the total treatment 
time, and hence anesthetic time, and MRI contrast 
agent injections were limited to two per treatment. No 
adverse events were observed following these 
modifications. 
Tissue analysis 
Table 3 details the results of the tissue analysis 
on a per-animal basis. There were no statistically 
significant reductions in Aβ load in the left 
hemisphere as compared to the right hemisphere in 
the single treatment group (t(4)=1.17 p=0.31) and 
loads were significant correlated across hemispheres 
(r=0.88 p=0.048). However, 3/5 dogs showed lower 
left prefrontal cortex loads (Fig.6 A,B) relative to the 
untreated right prefrontal cortex. In the multiple 
treatment condition, a similar result was observed 
with no statistically significant decreases in Aβ 
(t(4)=0.12 p=0.98) but the two hemispheres were not 
correlated (r=0.03 p=0.96). In this group, 3/5 dogs also 
showed lower left prefrontal cortex Aβ compared to 
right prefrontal cortex (Fig.6 C, D) but 2/5 animals 
did not show any clear reduction of Aβ (Fig. 6 E, F). . 
IBA-1 loads (Fig.7, Table 3) and the number of 
microhemorrhages (Table 3) in the prefrontal cortex 
were similar across hemispheres in both groups. In 
the single treatment group, the mean number of 
microhemorrhages in the treated side was 1.0 ± 1.4, 
compared with 0.4 ± 0.5 on the untreated side. In the 
multiple treatment condition, an average of 5.2 ± 1.8 
microhemorrhages were detected in on the treated 
size vs. 4.0 ± 2.0 on the contralateral size. Statistical 
analysis was not performed due to the extremely low 
counts. 
 
Table 3. Summary of treatment parameters and outcomes. (A - Fixed pressure, 0.33 Hz PRF, 3 minutes, 9 interleaved foci per sonication 
at 4 mm spacing; B - Actively controlled pressure, 1 Hz PRF, 2 minutes, up to 4 interleaved foci per sonication at 4.5 mm spacing; * 
Variations in the number of injections and sonication spots per treatment for the repeated treatments is a result of variables such as animal 
positioning (e.g. a different angle of the head requiring targeting at two different depths to ensure complete coverage of the brain) and 
incomplete sonications (e.g. software crash halting the treatment mid-sonication and requiring a second sonication) 
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3 M 11 11.7 1 B 9 36 normal none 5.1/5.1 52.7/51.3 2/1 
4 F 10 10.1 1 B 12 48 normal none 0.0/0.6 40.0/50.4 0/0 
5 F 10 12.1 1 B 13 52 normal none 26.4/51.3 36.8/35.8 3/1 
6 F 11 12 4 B 11/9/9/9 44/34/34/36 normal vomiting/ 
bloody urine 
18.1/31.0 24.8/22.4 3/2 
7 F 11 13.8 4 B 10/9/8/9 40/35/31/35 normal none 23.0/2.5 19.6/17.6 7/6 
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10 M 11 12.1 4 B 8/12/8/7 31/46/32/28 normal none 24.8/44.3 23.4/27.3 7/6 
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Fig.5. Mean enhancement of the treated hemisphere with respect to the 
contralateral hemisphere for all animals, expressed as (1-mean_intensitytreated/ 
mean_intensityuntreated)*100%. The enhancement values are averaged over the 
entire hemisphere. A control (unsonicated) region in the treated hemisphere is 
also shown (compared to the same contralateral, untreated region) to eliminate 
bias from spatial sensitivity of the MRI coil. The error bars indicate one standard 
deviation. 
Discussion  
This study presents the first investigation of BBB 
opening in a natural model of aging, and used a 
large-volume treatment scheme at low, skull 
penetrating frequency relevant to AD. These results 
show that after a total of 920 sonications, transient 
increase in the permeability of the BBB in a whole 
hemisphere is well tolerated in the aged brain 
following both single and repeated treatments 
without any MRI or histological observation of brain 
damage. One minor adverse event was observed, 
from which the animal fully recovered and could be 
attributable to effects from the anesthetic and/or MRI 
contrast agent. Preliminary histological evidence 
suggests that ultrasound treatments in a natural 
disease model is safe and in 3/5 of our animals, 
particularly in the repeated treatment condition, may 
also impact plaque pathology as has been seen in 
transgenic mouse models of AD [18, 19]. In this 
natural model of aging the amount of plaque 
pathology varied to a greater degree between animals 
than the transgenic models, where similar levels of 
burden are seen for animals of a given age. This 
canine model is therefore more representative of the 
clinical scenario, where patients present with varying 
levels of disease. Additionally, in this study the 
animals had a range of underlying pathology and it is 
possible that these pathologies may have interfered 
with the treatment outcomes. However, this is also 
more representative of what can be expected 
clinically, where older patients may have 
co-morbidities. Unfortunately this also means that a 
much larger group size would be needed to observe 
statistically significant changes in plaque load due to 
treatment. 
 
 
Fig.6. Representative examples of Aβ (6E10) immunostaining in the prefrontal 
cortex of aged beagles in response to treatment. In a single treatment, the left 
treated hemisphere shows less Aβ deposition (A) than the right untreated 
hemisphere (B). Similarly, the left hemisphere of a dog given 4 treatments (C) 
shows less Aβ than the right untreated hemisphere (D). In contrast, some dogs 
with significant Aβ neuropathology do not show hemisphere treatment effect (E 
– single treatment) and right untreated hemisphere (F). Panels A-F all have the 
same magnification and the scale bar is 1.5 mm. The quantification of the Aβ 
load is shown in panel (G) for the acute and chronic treatment groups. 
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Fig.7. Representative examples of microglial (IBA-1) immunostaining in the 
prefrontal cortex of aged beagles in response to treatment. In a single 
treatment, the left treated hemisphere shows similar microglial “loads” (A) to 
the right untreated hemisphere (B). Similarly, the left hemisphere of a dog given 
4 treatments (C) shows similar microglial “loads” to the right untreated 
hemisphere (D). Panels A-D all have the same magnification and the scale bar is 
800 μm. Higher magnification (scale bar 150 μm) of sections from a dog given 4 
treatments highlights the morphology of the microglial cells in the left prefrontal 
cortex (E) as compared to the right prefrontal cortex (F). The quantification of 
the microglial loads is shown in panel (G) for the acute and chronic treatment 
groups. 
 
The time course in this study is not ideal for 
detecting changes in microglia activation, based on 
work in transgenic mice showing that acutely (4 days) 
IBA-1 staining is enhanced, but that this effect does 
not persist to 15 days [17]. As the primary goal of this 
study was to assess safety, a follow-up period to 
monitor the animals was necessary, making it 
impossible to examine the acute microglial response 
given the small number of subjects available. Thus we 
decided to measure chronic microglial activation as a 
possible outcome from the ultrasound treatments, and 
found that in this natural model the results are in 
agreement with work in transgenic rodents where a 
sustained microglial response is not observed. 
In this study we used a single element focused 
transducer operating at a sufficiently low frequency to 
allow transcranial treatment without having to correct 
for phase distortions caused by the bone. In this 
canine model, the parietal bone is relatively flat and 
the animal can be positioned such that the sound has 
almost normal incidence to the bone, allowing this 
simple treatment platform to be used. However, the 
length of the focal zone for this transducer is long 
(~40mm) increasing the risk of non-negligible 
reflections from the skull base. In addition the large 
focal volume means that the exposure is controlled to 
the location receiving the highest exposure and the 
tissue heterogeneity in the focal volume is not 
compensated for. This can be seen in the variability of 
the contrast enhancement throughout the sonicated 
hemisphere. Further the mechanical scanning 
approach is relatively slow. In future studies, a large 
aperture phased array transducer that can 
electronically steer a tighter focal volume around the 
field would allow for faster treatments with better 
spatial control of the BBB opening [33]. 
Although comprehensive studies following 
repeated, small volume BBB opening in healthy 
non-human primates [12, 13] have been reported, 
these canine studies provide important insight into 
the safety of this treatment in aged dogs with 
significant Aβ neuropathology. Further, the 
disruption volume was much larger than has been 
reported before and was well tolerated, as was the use 
of multiple microbubble injections (up to 13) per 
treatment. A previous study in a porcine model tested 
multiple injections of bubbles at a reduced dose (0.002 
ml/kg) to allow up to 10 sonications to be performed 
while remaining within the recommended maximum 
dose limit [34], however our study suggests that even 
higher bubble doses may be safe for treatments 
requiring serial sonications, as evidenced by our 
successful use of up to 13 bubble injections at a dose of 
0.2 ml/kg per injection. These results suggest that 
ultrasound opening of the BBB in the aged brain may 
be a safe treatment option but these preliminary data 
also suggest the greatest benefit may be in 
middle-aged dogs prior to Aβ accumulation. Further 
studies are needed to determine if FUS has a positive 
impact on naturally occurring Aβ pathology. A larger 
beneficial effect might also be achieved in future 
studies by combining the FUS opening of the BBB 
with the delivery of a therapeutic, such as an Aβ 
antibody [6], if FUS alone cannot produce a 
therapeutically relevant effect.  
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In addition to the small group size, another 
limitation is that this study did not include a sham 
treatment group as a control for the behavior testing 
or histological analysis. However, the individuals 
performing the behavior analysis were blinded to the 
treatment hemisphere and the degree of BBB opening 
(as determined by MRI enhancement) achieved 
during treatment. Further, based on prior studies in 
aged beagles that have not undergone ultrasound 
treatments, it has been found that old dogs can have 
widely varying Aβ loads [35, 36]. However, to our 
knowledge, there are no studies directly comparing 
Aβ deposition in the left and right hemispheres of 
aging dogs, thus in future studies, it will be critical to 
include sham treated animals.  
Clinical Translation: A commercial device already 
exists that would allow this technique to be 
implemented in the clinic, and this device has 
previously been tested in a healthy, large animal 
model [34]. While the ultrasound frequency used in 
this study is comparable to the commercial device, 
some of the other study parameters may need to be 
adjusted to be used in clinic. As discussed above, the 
total dose of microbubbles/treatment was higher in 
this study than the clinically recommended limit. 
Although our study suggests that in the future a 
higher total bubble dose, given over multiple 
injections, could be safe, initially lower bubble doses 
will most likely be used, similar to the scheme 
described by [34]. During the repeated treatments we 
limited the total number of MR contrast agent 
injections to 2, following an adverse reaction. 
Similarly, in the clinical setting it would be important 
to limit the total dose of MR contrast. Finally, in our 
study we used an active control scheme to ensure a 
safe ultrasound exposure level. This controller is 
currently not implemented in an automated fashion 
on the commercial device, but a similar approach 
could be manually implemented by increasing 
exposures until the desired bubble behavior is 
observed by the operator. This study demonstrates 
the safety of this approach in a clinically-relevant 
disease model with large treatment volumes and 
paves the way for clinical testing in AD patients in the 
very near future. 
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